Chronic Lymphocytic Leukemia

Immune checkpoint inhibitor development is progressing as treatments for patients with acute myeloid leukemia and myelodysplastic syndrome, with a number of studies currently assessing new combination strategies.

Steven Coutre, MD, professor of medicine, Stanford University School of Medicine, discusses the benefits and drawbacks of the different frontline treatment options for chronic lymphocytic leukemia (CLL).

Alessandra Ferrajoli, MD, discusses the challenge with secondary malignancies in patients with CLL.

William G. Wierda, MD, PhD, discusses provided his expert insight on the frontline treatment of patients with CLL.

Chronic Lymphocytic Leukemia with Steven Coutre, MD

Chronic Lymphocytic Leukemia with Steven Coutre, MD

Chronic Lymphocytic Leukemia with Jan A. Burger, MD, PhD

Richard R. Furman, MD emphasizes that physicians should follow their best independent judgment regarding therapy selection in CLL, regardless of FDA approval.

A move by CVS Health to place in-house physician dispensaries out-of-network for purposes of Medicare Part D drug payment would force hundreds of thousands of cancer patients across the country to find alternate sources for their oral oncolytic drugs, the Community Oncology Alliance (COA) argued in a new white paper.

The positive opinion for the BCL-2 inhibitor has been sent to the European Commission, which usually issues its final approval decision within 2 to 3 months of the CHMP recommendation.

Steve Coutre, MD, discusses how he determines which CLL treatment option is best for which patient, the advantage of treating patients with ibrutinib over chemoimmunotherapy, and new oral agents currently being investigated in the space.

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the management of CLL treatment in the frontline setting.

William G. Wierda, MD, PhD, discusses which groups of CLL patients may benefit from ibrutinib versus chemoimmunotherapy and clinical trials that may provide further clarification.

Jennifer Brown, MD, PhD, discusses the status of targeted therapy agents for the treatment of patients with CLL.

Jennifer Woyach, MD, offers her expert insight into the practical clinical use of CLL treatments.

Nitin Jain, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, discusses the checkpoint inhibitors under investigation in chronic lymphocytic leukemia (CLL).

Focusing primarily on the therapeutic categories of PI3K and BTK inhibitors, O’Brien, associate director for clinical science at the Chao Comprehensive Cancer Center, acknowledged efforts to build on existing success but said the hoped-for progress and advances await definitive data.

Bruce Cheson, MD, outlines the treatment choices for each of the 3 patient categories of CLL, noting that, regardless of the treatment, “a clinical trial is always the preferred option.”

Results from the phase Ib M13-365 study showed combining the BCL-2 inhibitor venetoclax (Venclexta) with the anti-CD20 agent rituximab (Rituxan) led to objective responses in 86% of patients with relapsed/refractory chronic lymphocytic leukemia (CLL).